

# 온라인 세미나 사전 접수 안내

세미나 개요

한국비임상기술지원센터에서는 제 4회 온라인 세미나를 통해,항암제,자가면역질환 및 새로운 심장안정 성 평가 가이드라인 등과 같이 차세대 신약개발 과정에서 주요한 이점이 될 수 있는 주제들을 선별하였으 며, 참석해주시는 연구자 선생님에게 이러한 정보들을 공유해드리고자 합니다.

> 내 용

Time	Topics
13:30~ 13:35	Greeting
13:35~ 14:00	Tumour immunotherapy reversesT cell dysfunction and regulates Treg cells –Jun li Ph.D
14:00~14:05	Q/A Session
14:05 ~ 14:25	Innovative Models to Accelerate Development of Therapeutics for Autoimmune & Inflammatory Diseases – Jenna Frame Ph.D.
14:25~ 14:30	Q/A Session
14:30~ 14:40	Break Time
14:40~ 15:10	The application of biomarkers in oncology clinical trials-Dan liu
15:10~ 15:15	Q/A Session
15:15~15:45	Bioanalysis in Cell and Gene Therapy—Challenges and Solutions-JJ Chen Ph.D
15:45~15:50	Q/A Session
15:50~16:00	Break Time
16:00~16:25	Evaluation of Cardiac Safety Using Human Pluripotent Stem Cell-derived Cardiomyocytes- 우동훈 Ph.D
16:25~16:30	Q/A Session

대 상 자: 제약업체 연구원 및 관련기관 종사자

인 원: 선착순 200명 종료 시 마감

시: 2022년 03월 18일(금) 13:30~16:30

소: Zoom Webinar Online 개최

신청기간: 2022년 02월 18일(금)~ 2022년 03월 17일(목)

등 록 비: 무료

신청방법: 아래 링크에서 신청서 작성

https://forms.gle/51pKPSE1ainQGUsp8

(신청완료 후 한국비임상기술지원센터에서 신청확인 메일 발송 예정, 확인 메일 받은 자에 한해 교육 참석 가능)


문 의 처: Tel. 031-759-9934 / E-mail. mail@kntsc.kr 담당자. 원민규

✓ 교육 세션은 원활한 진행을 위해 레코딩으로 진행됩니다.

✓.사전질의에 한해서 웨비나 당일 Q/A를 진행 합니다

- √사전질의 사항이 있으신 경우 담당자의 메일 혹은 홈페이지 하단 안내 메일로 발송 부탁 드립니다.
- ✓세션1, 세션2, 세션3은 영어로 진행되며, 국문 자막이 제공됩니다..
  ✓온라인 세미나 진행중 퀴즈 이벤트가 있을 예정입니다.
- √퀴즈 이벤트는 당일 안내자의 공지에 따라 웨비나가 종료된 이후 참여만 인정 됩니다.





Jun Li(Ph.D.)

### Biocytogen Pharmaceuticals (Beijing) Co., Ltd

Dr. Jun Li graduated from University of Aberdeen with a BSc (Hons) in Biomedical Sciences in 2009. He continued to study and completed his PhD in Medical Sciences in the University of Aberdeen in 2013. He then worked as a postdoctoral scientist at the Cancer Research UK Edinburgh Centre of University of Edinburgh from 2014 to 2018. He joined Biocytogen (Beijing) in 2019 as an R&D scientist and then a study director. He is responsible for overseas CRO consultation and preclinical research of biotherapeutics.

## **Presentation Outline:**

In this webinar, we will review and discuss about:

- 1. T-cell dysfunction and Treg cells in cancer
- 2. Reversing T-cell dysfunction
- 3. Evaluation of anti-human TNFR2 and CCR8 antibodies in tumour models





Jenna Frame(Ph.D.)

## Sr. Scientist, Scientific Communications, Biocytogen Boston

Dr. Jenna Frame has worked with mouse and zebrafish models in the hematology field for over 15 years. At Biocytogen, Jenna helps provide researchers with the information they need to select quality animal models and other preclinical services to advance their research pipeline.

#### **Presentation Outline:**

# Innovative Models to Accelerate Development of Therapeutics for Autoimmune & Inflammatory Diseases

- Biocytogen is able to establish multiple autoimmune disease models including asthma, atopic dermatitis and psoriasis, etc.
- Biocytogen's humanized cytokine and cytokine receptor models such as B-hIL4/hIL4RA, B-hIL17A/hIL17F are powerful preclinical models to evaluate the in vivo efficacy and safety of novel antibody drugs for the treatment of autoimmune and inflammatory diseases.





## **CAREER EXPERIENCES/PROFESSIONAL POSITIONS AND EMPLOYMENTS**

2018-current, Head of department of biomarker and translational research 2014-2018, WuXi Biologics, Senior scientist 2010-2014, Visiting scientist, Penn State University/University of Maryland 2009-2010, Research Assistant, Fudan University Shanghai Cancer Center

#### **EDUCATION**

Southeast University, Clinical laboratory science, BS Fudan University, Biochemistry and molecular biology, MS





JJ [Jianjun] Chen (Ph.D.)

JJ (Jianjun) Chen, Ph.D., joined Shanghai Innostar Biotech. Co. ltd. on October 2020, served as Sr. Director of Macromolecular Bioanalysis Testing Business Department.

Ph.D. in Microbiology, Chinese Academy of Science, postdoctoral research in Depart of Surgery and Hematology/Oncology Depart of Medicine, University of Chicago, USA

Immunologist with more than 10 years of experience of research and drug development, ranging from basic research, preclinical study to clinical study; highly interdisciplinary knowledge base.

13 years of R&D experience on immunology, immune-oncology, vaccine, cell therapy from early discovery to PoC study and clinical study, published 18 high quality SCI articles.

Experience in immunology, macromolecular bioanalysis and biomarkers and transformational medicine (tumor immunity, cell therapy) in Teva Global R & D Center (USA), AstraZeneca (USA).

Rich experience in GLP and GCP method development and verification (PK, immunogenicity, biomarker).

Responsible for biological analysis, biomarkers, transformation medicine research of AstraZeneca cell therapy department, and promoted the application of IND and phase-I clinical development of AstraZeneca's first cell therapy product.

Established AstraZeneca early oncology Award for its first high-dimensional flow platform.





Dong-Hun Woo(Ph.D.)

#### CAREER EXPERIENCES/PROFESSIONAL POSITIONS AND EMPLOYMENTS

Postdoctoral Research Fellow (Nov. 2011 ~ Sep. 2013)

Dept. of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA

Postdoctoral Research Fellow (Oct. 2013 ~ Aug. 2016)

Dept. of Animal Biology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Chief Technology Officer (CTO, Sep. 2016 ~ present)

Chief Operating Officer (COO, Nov. 2018 ~ present)

NEXEL Co., Ltd., 8th Floor, 55 Magokdong-ro, Gangseo-gu, Seoul, Korea

Secretory for Industry-University Cooperation (July. 2018 ~ June. 2020)

Korean Organoid Society, Seoul, Korea

HESI Cardiac Safety Committee, Stem Cell Working Group (Nov. 2020 ~ present)

Core Expert in Evaluating Safety technology, Ministry of Food and Drug Safety (July. 2021~ present)

#### **EDUCATION**

1998 – 2004 Hanyang University, Seoul, Korea (B.S.)

2005 – 2007 Korea University, Seoul, Korea (M.S.)

2007 – 2011 Korea University, Seoul, Korea (Ph.D.)

2011 – 2013 Cleveland Clinic, Cleveland OH (Postdoc)

2013 – 2016 University of Pennsylvania, Philadelphia PA (Postdoc)